Grand Pharmaceutical Group (HKG:0512) will obtain the exclusive development and commercialization rights for two dry eye drugs from Corxel Pharmaceuticals Hong Kong for the Greater China region, a Wednesday bourse filing said.
The exclusive rights for the varenicline tartrate and simpinicline nasal sprays will cover the region comprising Mainland China, Hong Kong, Macau, and Taiwan.
Corxel is a biopharmaceutical company headquartered in the United States and China.